Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BioGend Therapeutics CoROCO:6733 -2.50%73 PB Ratio is 4.26 as of Jul. 14, 2026, which is 6% below its 10-year median of 4.53. GuruFocus rates ROCO:6733 with a GF Score™ of 73/100 and a GF Value™ of NT$70.22 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 1,228 Biotechnology companies, BioGend Therapeutics Co ranks worse than 64.9% on this metric.
The historical rank and industry rank for BioGend Therapeutics Co's PB Ratio or its related term are showing as below:
ROCO:6733'
s PB Ratio Range Over the Past 10 Years
Min: 2.43 Med: 4.53 Max: 7.49
Current: 4.26
During the past 10 years, BioGend Therapeutics Co's highest PB Ratio was 7.49. The lowest was 2.43. And the median was 4.53.
ROCO:6733's PB Ratio is ranked worse than 64.9% of 1228
companies
in the Biotechnology industry
Industry Median: 2.885
vs ROCO:6733: 4.26
During the past 12 months, BioGend Therapeutics Co's average Book Value Per Share Growth Rate was -9.30% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -4.30% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -5.10% per year.
During the past 10 years, the highest 3-Year average Book Value Per Share Growth Rate of BioGend Therapeutics Co was 20.70% per year. The lowest was -8.20% per year. And the median was -0.45% per year.
Back to Basics: PB Ratio
BioGend Therapeutics Co (ROCO:6733) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6733 vs VRTX, REGN, ALNY: PB Ratio Comparison
For the Biotechnology subindustry, BioGend Therapeutics Co's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioGend Therapeutics Co PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioGend Therapeutics Co's PB Ratio distribution charts can be found below:
* The bar in red indicates where BioGend Therapeutics Co's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
BioGend Therapeutics Co (ROCO:6733) has a PB Ratio of 4.26 as of Jul. 14, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on BioGend Therapeutics Co and its competitors. This is near median its historical median of 4.53. Over the past decade, BioGend Therapeutics Co's PB Ratio has ranged from 2.43 to 7.49. According to the industry distribution chart, BioGend Therapeutics Co ranks #797 out of 1228 companies in the Biotechnology industry, placing it in the top 64.9%.
Is BioGend Therapeutics Co's PB Ratio too high?
BioGend Therapeutics Co's current PB Ratio of 4.26 is near median its 10-year median of 4.53. Over the past 10 years, this metric has ranged from a low of 2.43 to a high of 7.49. The Biotechnology industry median PB Ratio is 2.89. BioGend Therapeutics Co's value of 4.26 is 47.7% above this industry median. Based on the distribution chart, BioGend Therapeutics Co ranks #797 out of 1228 companies in the Biotechnology industry, which is below the industry midpoint. Overall, BioGend Therapeutics Co has a GF Score™ of 73/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BioGend Therapeutics Co's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, BioGend Therapeutics Co ranks #797 out of 1228 companies for PB Ratio. This places BioGend Therapeutics Co in the lower half of its industry. The industry median PB Ratio is 2.89. BioGend Therapeutics Co's value of 4.26 is 47.7% above this benchmark. Historically, BioGend Therapeutics Co's own PB Ratio has ranged from 2.43 to 7.49 over the past decade. While the company's 10-year median is 4.53 vs. the industry median of 2.89, BioGend Therapeutics Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.89, based on 1,228 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioGend Therapeutics Co's current PB Ratio of 4.26 is 47.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on BioGend Therapeutics Co and its competitors. For the Biotechnology industry, the median PB Ratio is 2.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioGend Therapeutics Co's current PB Ratio is 4.26, which is near median its own 10-year median of 4.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioGend Therapeutics Co stock overvalued right now?
Based on GuruFocus' analysis, BioGend Therapeutics Co (ROCO:6733) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$70.22, compared to a current price of NT$25.35 — trading 63.9% below its estimated fair value. The current PB Ratio is 4.26, which is near median its 10-year median of 4.53 and 47.7% above the Biotechnology industry median of 2.89. BioGend Therapeutics Co's overall GF Score™ is 73/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For BioGend Therapeutics Co (ROCO:6733), the current PB Ratio is 4.26 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioGend Therapeutics Co (ROCO:6733) Overvalued in 2026?
Based on GuruFocus' analysis, BioGend Therapeutics Co stock appears to be undervalued.
The current stock price of NT$25.35 is trading 63.9% below its estimated GF Value™ of NT$70.22.
GuruFocus considers BioGend Therapeutics Co to be Significantly Undervalued.
Key valuation signals for ROCO:6733:
PB Ratio: 4.26 (near median its 10-year median of 4.53)
GF Value™: NT$70.22 vs. price of NT$25.35 (63.9% below fair value)
Industry Position: 47.7% above the Biotechnology median (#797 of 1228)
No single metric tells the full story. See the ROCO:6733 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioGend Therapeutics Co Ltd is a Taiwan-based company involved in the research and development of orthopedic medical equipment and related products, and the sale of related products. It is involved in the research and development of inventive cartilage repair technology and products, adipose stem cell extraction technology, and others. Geographically, the company generates a majority of its revenue from Taiwan, followed by China, Malaysia, and other regions.
73GF Score
Get the complete analysis for ROCO:6733
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6733 has been successfully added to your 
